

**S2 Table.** Comparison of baseline confirmed by repeated testing and re-assessed HER2 status in patients with baseline HER2 negativity

Baseline HER2 status (best)	No. (%) (n=77)	Re-assessed HER2 status	No. (%)
IHC 0	56 (72.7)	IHC 0	51/56 (91.1)
		IHC 1+	4/56 (7.1)
		IHC 2+/ISH-	0
		IHC 2+/ISH+	1/56 (1.8)
		IHC 3+	0
IHC 1+	17 (22.1)	IHC 0	11/17 (64.7)
(Initial/Repeated)		IHC 1+	5/17 (29.4)
IHC 0/IHC 1+	9/17	IHC 2+/ISH-	1/17 (5.9)
IHC 1+/IHC 0	3/17	IHC 2+/ISH+	0
IHC 1+/IHC 1+	5/17	IHC 3+	0
IHC 2+/ISH-	4 (5.2)	IHC 0	2/4 (50.0)
(Initial/Repeated)		IHC 1+	1/4 (25.0)
IHC2+ & ISH-/IHC0	2/4	IHC 2+/ISH-	0
IHC0/IHC2+ & ISH-	2/4	IHC 2+/ISH+	0
		IHC 3+	1/4 (25.0)

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, *in situ* hybridization.